CB Therapeutics is building a synthetic biology platform to solve mankind's most challenging mental healthcare and social challenges.

Whitefish, Montana--(Newsfile Corp. - October 6, 2020) - (OTCQB: CNFN), owner and operator of CFN Media, the leading media network and agency dedicated to the global legal cannabis, CBD and psychedelics industries, today announced the addition of to its growing client roster in the psychedelics industry.

CB Therapeutics logo

To view an enhanced version of this graphic, please visit:

CFN Media will leverage its , a leading index that tracks the public and private psychedelic markets, along with its core digital content and distribution platform, to attract interested retail, accredited and institutional investors to CB Therapeutics.

"Researchers have realized the potential for psychedelics to transform mental healthcare," said CFN Media President Frank Lane. "CB Therapeutics is leveraging cutting-edge yeast cultivation and protein engineering techniques to develop high-value psychedelics compounds at scale with a significant reduction in costs and at over 99% purity-a breakthrough for the industry."

The psychedelics industry is projected to reach nearly $7 billion by 2027, according to , which represents a 16.3% compound annual growth rate. The growth is driven by increasing prevalence of depression and other mental health disorders and a growing acceptance of psychedelic drugs for the treatment of depression.

CB Therapeutics has built an IP portfolio that spans the entire production process from microorganisms to final products. With a state-of-the-art pilot facility in California, the company has already demonstrated its innovative approach in-house where it uses synthetic biology to develop and produce a range of high-value cannabinoids and psychedelic compounds.

"We are very fortunate to be the first private company to develop cutting-edge biosynthesis solutions for producing tryptamines such as psilocybin, psilocin, DMT, bufotenine, and many other high value compounds. Building off our scalable and modular cellular agriculture platform, we've been early movers with IP filing and at the forefront of producing libraries of novel cannabinoid and tryptamine analogs. As this industry grows, there will be a significant need for low cost, high purity molecules and analogs, and biosynthesis is the cleanest and most efficient way to do it," said Sher Ali Butt, CEO of CB Therapeutics.

About CB Therapeutics

, located in San Diego, California, is a biotechnology company focusing on the innovative production of high value molecules, compounds and rare ingredients from simple feedstock utilizing many different types of hosts and systems, including yeast, bacteria and cell-free expression systems. CB Therapeutics' expertise in synthetic genomics, bio-engineering and cellular production processes can produce a broad range of phytochemicals faster, more sustainably, at greater yields and with higher purity, consistency and efficiency than competitive platforms.

About CFN Enterprises Inc.

CFN Enterprises Inc. (OTCQB: CNFN) is a digital media and ecommerce company focused on advancing businesses and brands in highly regulated emerging industries across the globe. CFN connects investors with new market opportunities while helping consumers find innovative products that enhance their lives. Learn more at .

CFN Enterprises Inc. Media Contact:

CFN Enterprises Inc.
+001 (833) 420-CNFN

FORWARD-LOOKING STATEMENT

Use of Forward-looking Statements

This press release may contain forward-looking statements from CFN Enterprises Inc. within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when CFN Enterprises Inc. describes the potential acquisition of BarNone assets and the related benefits, its pursuit of M&A opportunities, growth in CBD sales and spending on affiliate marketing, and uses other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, CFN Enterprises Inc. is using forward-looking statements. These forward-looking statements are based on the current expectations of the management of CFN Enterprises Inc. only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial markets; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in applicable laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products and services; or, loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of CFN Enterprises Inc. to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, CFN Enterprises Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting CFN Enterprises Inc., reference is made to CFN Enterprises Inc.'s reports filed from time to time with the Securities and Exchange Commission.

To view the source version of this press release, please visit